Disseminated intravascular coagulation future or investigational therapies

Jump to navigation Jump to search

Disseminated intravascular coagulation Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Disseminated intravascular coagulation from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiograph and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Disseminated intravascular coagulation future or investigational therapies On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Disseminated intravascular coagulation future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Disseminated intravascular coagulation future or investigational therapies

CDC on Disseminated intravascular coagulation future or investigational therapies

Disseminated intravascular coagulation future or investigational therapies in the news

Blogs on Disseminated intravascular coagulation future or investigational therapies

Directions to Hospitals Treating Disseminated intravascular coagulation

Risk calculators and risk factors for Disseminated intravascular coagulation future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Future or Investigational Therapies

  • Phase I trials suggest that infusion of activated protein C may also benefit patients with DIC.
    • The theory is that APC normally inactivates Va and VIIIa, resulting in a decrease in thrombin formation, and promotes fibrinolysis by inactivating plasminogen activator inhibitor.
  • Tissue factor pathway inhibitor has been shown to decrease mortality in baboon models of DIC with E. coli septic shock.
  • Agents such as ASA (aspirin), ticlopidine, dextran and GP IIb/IIIa inhibitors are also being examined with the goal of reducing platelet activation.
  • Currently, if fibrinolysis and hemorrhage appears to be more of a problem than clotting, the only options are antifibrinolytic agents, such as tranexamic acid. However, the risks of microvascular clot formation have limited its use.

References

Template:WH Template:WS